1. L. X. Yu. Bioequivalence of highly variable drugs: issues and challenges. Advisory Committee for Pharmaceutical Sciences Meeting Transcript, April 14, 2004.
http://www.fda.gov/ohrms/dockets/ac/04/transcripts/4034T2.pdf
(accessed 8/22/07).
2. Title 21, Code of Federal Regulations. Section 320.1. U.S. Government Printing Office, Washington, D.C., revised 2008.
3. U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations. March 2003, BP. Revision 1.
http://www.fda.gov/cder/guidance/5356fnl.pdf
(accessed 8/13/07).
4. U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Statistical Approaches to Establishing Bioequivalence, January 2001, BP.
http://www.fda.gov/cder/guidance/3616fnl.pdf
(accessed 8/13/07).
5. C. E. Diliberti. Why bioequivalence of highly variable drugs is an issue. Advisory Committee for Pharmaceutical Sciences Meeting Transcript, April 14, 2004.
http://www.fda.gov/ohrms/dockets/ac/04/transcripts/4034T2.pdf
(accessed 8/12/07).